🛰️ Daily AI Frontier
‹ back to 2026-09-25

A design approach for bitopic kinase inhibitors

Research Bioinformatics AI

Ranking

Overall 70
Content 80
Popularity 45

Observed public metrics from 1 member.

Merged summary

TL;DR - This Nature study presents a design strategy for bitopic kinase inhibitors that simultaneously engage two binding regions. Applying it to ABL1 and EGFR produced an ABL1 inhibitor with improved activity against resistance mutations and reduced off-target toxicity.

  • The approach systematically evaluates ligand choice, linkage vector, and linker length.
  • Bitopic inhibitors were developed for both ABL1 and EGFR kinases.
  • The reported ABL1 inhibitor showed enhanced activity against resistance mutations.
  • Reduced off-target toxicity suggests potential for more selective kinase therapies.

Sources (1)

A design approach for bitopic kinase inhibitors

Nature Jack W. Stevenson, Kevin Lou, Joshua A. Reynolds, Ian R. Outhwaite, Kenneth Huang, Ivan Sokirniy, Sky Y. J. Peterson, Amir Z. Munir, Celine D. Wang, Haider Inam, Emma L. Gebauer, Ariel Leyte-Vidal, Anastasiia Grynyova, Sydney M. Figueroa, Matthew G. Rees, Melissa M. Ronan, Fernando Salangsang, Yan Zeng, Veronica Steri, Jennifer A. Roth, Neil P. Shah, Ignacia Echeverria, Andrej Ĺ ali, Ziyang Zhang, Javid J. Moslehi, Markus A. Seeliger, Justin R. Pritchard, Kevan M. Shokat 2026-09-23 doi:10.1038/s41586-026-11056-8
Public signals OpenAlex citations 0
Providers: Hugging Face · N/A OpenAlex · Citations 0 Publisher · N/A Semantic Scholar · N/A X · N/A Fetched 2026-09-26 14:13:49.896947 UTC

TL;DR - This Nature study presents a design strategy for bitopic kinase inhibitors that simultaneously engage two binding regions. Applying it to ABL1 and EGFR produced an ABL1 inhibitor with improved activity against resistance mutations and reduced off-target toxicity.

  • The approach systematically evaluates ligand choice, linkage vector, and linker length.
  • Bitopic inhibitors were developed for both ABL1 and EGFR kinases.
  • The reported ABL1 inhibitor showed enhanced activity against resistance mutations.
  • Reduced off-target toxicity suggests potential for more selective kinase therapies.
item →